September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
2 citations
,
January 2010 in “Side effects of drugs annual” Dermatological drugs and cosmetics can cause serious side effects like cancer, allergies, and heart issues.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
22 citations
,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
474 citations
,
January 2012 in “Chemistry & biology” Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.
13 citations
,
January 1999 in “Postgraduate Medicine” New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
14 citations
,
April 2017 in “American Journal of Transplantation” Skin problems from transplant drugs are common and need careful management in organ transplant patients.
11 citations
,
July 1984 in “Australian Veterinary Journal” Some treatments worked for horse ringworm, but mass treatment should focus on stopping infection spread, not just hair regrowth.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
April 2018 in “Journal of Investigative Dermatology” Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
2 citations
,
November 2025 in “British Journal of Pharmacology” Daprodustat, combined with PAβN, could be a new antibacterial treatment.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
97 citations
,
January 1996 in “Clinical infectious diseases/Clinical infectious diseases (Online. University of Chicago. Press)” Fluconazole is somewhat effective for skin-related sporotrichosis but less so for severe forms, and should be a backup treatment.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.